Biotech

All Articles

Kairos goes public with $6M IPO to finance tests of cancer cells medicine

.Along with a trio of biotechs hitting the Nasdaq on Friday, it was simple to miss out on a smaller-...

Vaccine and also Keytruda combination efficient in squamous cell carcinoma

.Invulnerable checkpoint inhibitors are the superheroes of cancer treatment. Medications like Bristo...

Cue Biopharma queues up J&ampJ vet as CBO-- Chutes &amp Ladders

.Accept to today's Chutes &amp Ladders, our roundup of substantial leadership hirings, firings and a...

Regeneron's Opdualag competitor presents 57% action rate

.Regeneron is back with lasting consequence for its own LAG-3 prevention and also PD-1 inhibitor com...

AstraZeneca articles information on in-house competitors to AbbVie, Pfizer ADCs

.AstraZeneca has discussed an early take a look at the performance of its own internal antibody-drug...

iTeos- GSK's TIGIT superstar shows meaningful remodeling

.After announcing a phase 3 launch based on good midstage outcomes, iTeos and also GSK are eventuall...

More collective FDA can easily increase uncommon ailment R&ampD: document

.The FDA needs to be actually more available and collective to discharge a surge in commendations of...

Zenas, MBX, Bicara head to Nasdaq in very hot day for biotech IPOs

.It is actually an extraordinarily hectic Friday for biotech IPOs, along with Zenas BioPharma, MBX a...

Atea's COVID antiviral stops working to stop hospital stays in phase 3

.Atea Pharmaceuticals' antiviral has actually fallen short yet another COVID-19 test, however the bi...

Neurocrine's offer to save schizophrenia possibility falls short

.Neurocrine Biosciences' schizophrenia course pivot has actually stopped working. The biotech was ac...